lanthanum carbonate has been researched along with Calcinosis in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (47.83) | 29.6817 |
| 2010's | 10 (43.48) | 24.3611 |
| 2020's | 2 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Fujii, H; Goto, S; Kono, K; Nishi, S; Watanabe, K | 1 |
| Fujii, H; Hamano, T; Isaka, Y; Koiwa, F; Sakaguchi, Y; Tanaka, R; Tatsugami, F; Teramukai, S; Tomiyama, N; Tsujimoto, Y | 1 |
| Wang, S; Zhang, C; Zhang, X; Zhao, S | 1 |
| Chen, KH; Hsiao, CC; Lee, CC | 1 |
| Furuya, R; Hidaka, S; Ishioka, K; Iwagami, M; Kobayashi, S; Maesato, K; Mochida, Y; Moriya, H; Ohtake, T; Oka, M; Tsutsumi, D | 1 |
| Akhtar, J; Chen, B; Wang, H; Wang, R; Yu, C; Zhang, H; Zhao, T | 1 |
| Akhtar, J; Bing, C; Che, Y; Kezhou, Y; Rong, W; Tingting, Z | 1 |
| Wada, K; Wada, Y | 1 |
| Kitazono, T; Noguchi, H; Ooboshi, H; Tatsumoto, N; Tokumoto, M; Tsuruya, K; Yamada, S | 1 |
| Valdivieso, JM | 1 |
| Fernandez Giraldez, E; Sánchez González, MC; Valdivielso Revilla, JM | 1 |
| Spasovski, G | 1 |
| Chen, B; D'Haese, PC; Dams, G; De Broe, ME; De Clerck, N; Neven, E; Persy, V; Postnov, A | 1 |
| Alonso, M; Andrés, E; Ballarín, J; Bover, J; Canal, C; Farré, N; Olaya, MT; Quílez, B | 1 |
| Kerr, PG; Lau, KK; Polkinghorne, KR; Toussaint, ND | 1 |
| Moe, SM; Moorthi, RN | 1 |
| Evenepoel, P; Meijers, B | 1 |
| Albaaj, F; Hutchison, A | 1 |
| Amor, J; Palma, A | 1 |
| Bellinghieri, G; Calò, LA; Monardo, P; Santoro, D; Savica, V | 1 |
| Brancaccio, D; Cozzolino, M | 2 |
| Bellinghieri, G; Santoro, D; Savica, V | 1 |
8 review(s) available for lanthanum carbonate and Calcinosis
| Article | Year |
|---|---|
[Experimental advances in mineral metabolism].
Topics: Animals; Calcinosis; Calcium; Cardiovascular Diseases; Chelating Agents; Chelation Therapy; Chronic Disease; Drug Evaluation, Preclinical; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Intestinal Absorption; Kidney; Kidney Diseases; Lanthanum; Phosphorus; Sodium-Phosphate Cotransporter Proteins | 2008 |
[Control of phosphorus and treatment with vitamin D in chronic kidney disease prior to the start of dialysis].
Topics: Calcifediol; Calcinosis; Calcitriol; Cardiovascular Diseases; Chronic Disease; Chronic Kidney Disease-Mineral and Bone Disorder; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Phosphorus; Polyamines; Prevalence; Renal Dialysis; Sevelamer; Vitamin D; Vitamin D Deficiency | 2008 |
New strategies in treatment of mineral and bone disorders and associated cardiovascular disease in patients with chronic kidney disease.
Topics: Calcinosis; Cardiovascular Diseases; Chronic Disease; Humans; Kidney Diseases; Lanthanum; Minerals; Parathyroid Hormone; Phosphates; Polyamines; Sevelamer | 2008 |
Update on the treatment of chronic kidney disease-mineral and bone disorder.
Topics: Aluminum Compounds; Calcinosis; Calcium Carbonate; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Diet, Protein-Restricted; Dietetics; Humans; Kidney Failure, Chronic; Lanthanum; Naphthalenes; Nephrology; Nutrition Assessment; Nutritive Value; Parathyroidectomy; Patient Care Team; Patient Education as Topic; Phosphorus; Polyamines; Practice Guidelines as Topic; Sevelamer; Vitamin D | 2009 |
Hyperphosphataemia in renal failure: causes, consequences and current management.
Topics: Aluminum; Calcinosis; Calcitriol; Calcium; Cardiovascular Diseases; Chlorides; Epoxy Compounds; Humans; Hyperparathyroidism; Kidney Failure, Chronic; Lanthanum; Magnesium; Phosphates; Polyamines; Polyethylenes; Renal Dialysis; Sevelamer; Uronic Acids; Zirconium | 2003 |
[Management of hyperphosphoremia].
Topics: Calcinosis; Calcium; Case Management; Chelating Agents; Chelation Therapy; Epoxy Compounds; Humans; Hyperparathyroidism, Secondary; Iron; Kidney Failure, Chronic; Lanthanum; Phosphorus; Polyamines; Polyethylenes; Sevelamer | 2003 |
Phosphate binders and management of hyperphosphataemia in end-stage renal disease.
Topics: Acetates; Aluminum Compounds; Bone Diseases, Metabolic; Calcinosis; Calcium Carbonate; Calcium Compounds; Cardiovascular Diseases; Central Nervous System Diseases; Chronic Kidney Disease-Mineral and Bone Disorder; Diet, Protein-Restricted; Ferric Compounds; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Lanthanum; Phosphates; Phosphorus, Dietary; Polyamines; Renal Dialysis; Sevelamer | 2006 |
Emerging drugs for hyperphosphatemia.
Topics: Animals; Atherosclerosis; Calcinosis; Calcium Phosphates; Chelating Agents; Drugs, Investigational; Humans; Kidney Failure, Chronic; Lanthanum; Phosphates; Phosphorus Metabolism Disorders; Polyamines; Renal Dialysis; Saliva; Sevelamer; Uremia | 2007 |
5 trial(s) available for lanthanum carbonate and Calcinosis
| Article | Year |
|---|---|
Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients.
Topics: Adult; Aged; Calcinosis; Coronary Artery Disease; Disease Progression; Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Sequestering Agents; Sucrose; Young Adult | 2021 |
Effect of lanthanum carbonate on coronary artery calcification and bone mineral density in maintenance hemodialysis patients with diabetes complicated with adynamic bone disease: A prospective pilot study.
Topics: Administration, Oral; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases; Calcinosis; Calcium Carbonate; Coronary Artery Disease; Diabetes Complications; Female; Fibroblast Growth Factor-23; Humans; Lanthanum; Male; Middle Aged; Pilot Projects; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome | 2017 |
Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study.
Topics: Aged; Calcinosis; Calcium; Calcium Carbonate; Chelating Agents; Coronary Artery Disease; Disease Progression; Female; Follow-Up Studies; Humans; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Pilot Projects; Prospective Studies; Renal Dialysis; Time Factors; Treatment Outcome | 2013 |
Evaluation of aortic calcification with lanthanum carbonate vs. calcium-based phosphate binders in maintenance hemodialysis patients with type 2 diabetes mellitus: an open-label randomized controlled trial.
Topics: Aged; Aortic Diseases; Calcinosis; Calcium Carbonate; Chelating Agents; Diabetes Mellitus, Type 2; Disease Progression; Female; Humans; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Tomography, X-Ray Computed | 2014 |
Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial.
Topics: Adult; Aged; Aortic Diseases; Aortography; Biomarkers; Bone Density; Calcinosis; Calcium; Calcium Carbonate; Chelating Agents; Disease Progression; Female; Humans; Kidney Diseases; Lanthanum; Linear Models; Lumbar Vertebrae; Male; Middle Aged; Parathyroid Hormone; Phosphates; Pilot Projects; Renal Dialysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Victoria | 2011 |
10 other study(ies) available for lanthanum carbonate and Calcinosis
| Article | Year |
|---|---|
Comparison of the effects of lanthanum carbonate and calcium carbonate on the progression of cardiac valvular calcification after initiation of hemodialysis.
Topics: Aged; Aged, 80 and over; Biomarkers; Calcinosis; Calcium Carbonate; Chelating Agents; Disease Progression; Female; Heart Valve Diseases; Humans; Kidney Diseases; Lanthanum; Male; Middle Aged; Phosphorus; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Time Factors; Treatment Outcome | 2020 |
Successful Treatment of Tumoral Calcinosis by Lanthanum Carbonate.
Topics: Adult; Calcinosis; Calcium; Female; Gastrointestinal Absorption; Humans; Lanthanum; Lupus Erythematosus, Systemic; Phosphates; Treatment Outcome | 2018 |
High phosphate feeding induced arterial medial calcification in uremic rats: roles of Lanthanum carbonate on protecting vasculature.
Topics: Animals; Calcinosis; Collagen Type II; Core Binding Factor Alpha 1 Subunit; Down-Regulation; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Hyperphosphatemia; Integrin-Binding Sialoprotein; Lanthanum; Male; Osteocalcin; Phosphates; Phosphorus, Dietary; Rats; Transcription Factors; Tunica Media; Uremia | 2013 |
Lanthanum carbonate prevents accelerated medial calcification in uremic rats: role of osteoclast-like activity.
Topics: Acid Phosphatase; Animals; Calcinosis; Cathepsin K; Core Binding Factor Alpha 1 Subunit; Enzyme-Linked Immunosorbent Assay; Hyperphosphatemia; Isoenzymes; Lanthanum; Osteocalcin; Osteoclasts; RANK Ligand; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Tartrate-Resistant Acid Phosphatase; Uremia | 2013 |
Phosphate binders prevent phosphate-induced cellular senescence of vascular smooth muscle cells and vascular calcification in a modified, adenine-based uremic rat model.
Topics: Adenine; Animal Feed; Animals; Calcinosis; Calcium Carbonate; Cellular Senescence; Disease Models, Animal; Disease Progression; Fibrosis; Immunohistochemistry; Inflammation; Kidney; Kidney Failure, Chronic; Lanthanum; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Oxidative Stress; Phosphates; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Signal Transduction; Uremia; Vascular Calcification | 2015 |
Adequate phosphate binding with lanthanum carbonate attenuates arterial calcification in chronic renal failure rats.
Topics: Animals; Arteries; Bone and Bones; Calcinosis; Chondrogenesis; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Osteogenesis; Phosphates; Rats; Rats, Wistar; Vascular Diseases | 2009 |
CKD-mineral and bone disorder: core curriculum 2011.
Topics: Bone Diseases; Calcinosis; Calciphylaxis; Calcitriol; Calcium; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Kidney; Kidney Failure, Chronic; Kidney Tubules; Lanthanum; Parathyroid Hormone; Parathyroidectomy; Phosphorus; Polyamines; Practice Guidelines as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer; Vitamin D | 2011 |
Chronic kidney disease: Phosphate binder therapy--cracks in the tower of strength?
Topics: Acetates; Blood Vessels; Calcinosis; Calcium Compounds; Chelating Agents; Disease Progression; Humans; Hyperphosphatemia; Lanthanum; Phosphate-Binding Proteins; Phosphates; Polyamines; Renal Insufficiency, Chronic; Sevelamer | 2012 |
Optimising the treatment of hyperphosphatemia and vascular calcification in chronic kidney disease.
Topics: Atherosclerosis; Calcinosis; Calcium Phosphates; Chelating Agents; Drugs, Investigational; Humans; Kidney Failure, Chronic; Lanthanum; Phosphates; Phosphorus Metabolism Disorders; Polyamines; Renal Dialysis; Sevelamer; Uremia | 2007 |
Clinical consequences and novel therapy of hyperphosphatemia: Lanthanum carbonate for dialysis patients.
Topics: Calcinosis; Chelating Agents; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Lanthanum; Polyamines; Renal Dialysis; Sevelamer; Vascular Diseases | 2007 |